Assessment of venous thromboembolic disease (VTE) in oncology and haematology patients who presented to the Launceston General Hospital for treatment of their malignant disorder

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12611000762954

Enrollment

766

Registered

2011-07-21

Start date

2009-01-01

Completion date

2011-12-31

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Although most patients with different blood cancers and solid tumours present with clotting, there is little known about how many patients develop these complications and what risk factors are involved. This study will investigate all patients with cancer and develop blood clots at adult age group who are treated at the Launceston General Hospital for their cancer. The data of the trial will help us enormously to understand and know the risk factors for developing clots among this high-risk group of patients. This trial has the potential to change the treatment approach and the preventive strategies for cancer patients at all ages to improve outcome and benefit all patients avoiding serious complications of treatment of cancer. This trial may able to change the current protocols for prevention of clots during the treatment of oncology patients by applying the best preventive strategy against blood clotting. We are aiming to publish these data and the trial results in adequate international peer reviewed medical journal.

Interventions

This study will investigate all patients with cancer and develop blood clots at adult age group who are treated at the Launceston General Hospital (LGH) for their cancer during a period of 12 months. The data of the trial will help us enormously to understand and know the risk factors for developing clots among this high-risk group of patients. This trial has the potential to change the treatment approach and the preventive strategies for cancer patients at all ages to improve outcome and b

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

patients with hematological and malignant disorder who are over 18 years and presented with thromboembolic event to the Launceston General Hospital during the study period.

Exclusion criteria

patients below 18 years of age and who may present outside the study period range.

Outcome results